Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Minerva Pediatrica 2018 February;70(1) > Minerva Pediatrica 2018 February;70(1):59-66

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Pediatrica 2018 February;70(1):59-66

DOI: 10.23736/S0026-4946.17.05147-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Safety of HPV vaccines in the age of nonavalent vaccination

Filippo QUATTRONE , Alice CANALE, Elisa FILIPPETTI, Alberto TULIPANI, Andrea PORRETTA, Pier L. LOPALCO

Unit of Hygiene and Epidemiology, Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy


PDF


To date three vaccines against human papilloma virus (HPV) have been licensed: a bivalent, a quadrivalent and, in 2014, a nonavalent vaccine. Despite the early implementation of national vaccination programs, in the majority of developed countries coverage rates remain unsatisfactory. Rumors about vaccine safety have been one of the principal obstacles for the acceptance of HPV vaccination by the public. It is therefore of primary importance to provide the public with clear and up-to-date information about HPV vaccination safety. To this aim, in this narrative review we will summarize safety data from pre and postlicensure studies for the three HPV vaccines available with a focus on the safety profile of the new nonavalent vaccine.


KEY WORDS: Papillomavirus vaccines - Vaccines - Review

inizio pagina